AccuStem Sciences Inc. reported a net loss of $1.76 million for the fiscal year ending December 31, 2025, an increase from a loss of $1.51 million in the previous year. The company's accumulated deficit now stands at $9.78 million. The increase in losses is attributed primarily to heightened research and development expenses, which rose to $281,014 from $138,324 in 2024, reflecting intensified efforts in technology transfer activities. General and administrative expenses also increased by 8% to $1.48 million, driven by higher public relations, travel, and professional fees.
In terms of operational developments, AccuStem is focused on the commercialization of its proprietary genomic tests, MSC (MicroRNA Signature Classifier) for lung nodules and StemPrintER for early-stage breast cancer. The company estimates a market opportunity exceeding $6.3 billion in the U.S. for these tests. The MSC test has been validated in over 5,000 patients, while StemPrintER has been validated in more than 3,000 patients. AccuStem has partnered with EmeritusDx to establish a laboratory for processing and reporting test results, with plans to seek CLIA certification to enable clinical use and reimbursement from Medicare.
As of December 31, 2025, AccuStem had four full-time employees and reported a cash balance of $13,929, which is insufficient to support operations beyond January 2026. The company is actively pursuing additional funding to support its research and development activities, as well as to cover operational costs. The financial statements indicate that the company has relied heavily on advances from related parties, with a related party payable of $4.22 million as of the end of 2025.
Looking ahead, AccuStem anticipates continued operating losses and recognizes the need for substantial additional funding to complete the development of its product candidates. The company is exploring various financing options, including equity and debt financing, but acknowledges the uncertainty surrounding the availability of such funding. The management has expressed concerns about the company's ability to continue as a going concern, given its recurring losses and the need for significant capital to sustain operations and support product development.
In summary, AccuStem Sciences Inc. is navigating a challenging financial landscape as it seeks to bring its innovative diagnostic tests to market. The company is focused on securing necessary funding and achieving key operational milestones, while also addressing the risks associated with its ongoing development efforts and market competition.
About Accustem Sciences Inc.
AccuStem Sciences, Inc. is a clinical-stage diagnostics company developing proprietary genomic tests to improve cancer patient outcomes. Its key products include the MSC test for lung nodule malignancy risk and StemPrintER, a multi-gene assay predicting breast cancer recurrence risk. Targeting oncology care providers and patients, AccuStem leverages validated molecular diagnostics to support personalized treatment decisions, focusing initially on the U.S. market with plans for broader tumor applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.